[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing First Hospital, Nanjing Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":636},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,74,0,25,[9,43,76,101,127,150,173,200,226,249,272,300,323,344,372,398,426,445,466,488,511,540,567,587,611],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100641812","mechanistic-study-of-pk2-pathway-in-alleviating-perioperative-neurocognitive-disorders-by-improving-neurometabolic-uncoupling-100641812",false,"NCT07652008","Mechanistic Study of PK2 Pathway in Alleviating Perioperative Neurocognitive Disorders by Improving Neurometabolic Uncoupling","Inclusion Criteria:\n\n* Age ≥ 65 years and ≤ 80 years\n* ASA physical status Class Ⅰ-Ⅲ\n* Elderly patients undergoing hip replacement surgery\n\nExclusion Criteria:\n\n* Mini-Mental State Examination (MMSE) score ≤ 24\n* Severe cardiac, pulmonary, hepatic or renal dysfunction\n* Recent use of sedatives or antidepressants, or alcohol abuse\n* Patients with severe mental disorders including depression, schizophrenia, bipolar disorder, mental retardation, etc.\n* History of severe craniocerebral injury, cerebrovascular disease, hydrocephalus, intracranial tumor, or other neurological diseases (e.g., Parkinson's disease, Huntington's disease, epilepsy)\n* Severe visual or hearing impairment\n* Inability to complete cognitive function tests due to advanced age, low educational level, or other factors",true,"ALL","65 Years","80 Years",{"count":21,"type":22},40,"ESTIMATED","OBSERVATIONAL","The term perioperative neurocognitive disorders (PND) is derived from postoperative cognitive dysfunction (POCD), and has been renamed as PND in recent years in accordance with the latest international consensus. PND specifically refers to changes in mental, social and cognitive abilities in patients following surgery; in severe cases, personality changes and reduced social functioning may also occur. As a serious complication affecting the central nervous system (CNS), apart from surgical trauma, advanced age is widely recognized as a critical factor contributing to the development and progression of PND. Its adverse effects represent a major challenge for the rapidly growing elderly population worldwide.\n\nIt is currently believed that the decline in cognitive functions such as memory and attention observed in some patients after surgery may be associated with inflammatory responses in the brain. Surgical stress may activate supporting cells in the brain, such as astrocytes. When these cells are abnormally activated, they may fail to maintain normal neuronal function, thereby disrupting brain homeostasis and leading to cognitive impairment.\n\nRecent studies have shown that these glial cells exert distinct effects on neurons under different phenotypes: some phenotypes promote neural repair and protection, whereas others exacerbate neural injury. Evidence suggests that in multiple neurological disorders, the pro-inflammatory phenotype of glial cells is closely associated with cognitive impairment.\n\nProkineticin-2 (PK2) is an endogenous signaling molecule involved in the regulation of diverse physiological processes, including inflammatory responses, energy metabolism, and neuroprotection. Previous studies have demonstrated that PK2 exerts protective effects in various neurological disease models, improving neuronal function and alleviating cognitive or motor deficits. Our preliminary animal experiments revealed reduced brain PK2 levels, especially in memory-related regions, in mice with postoperative cognitive dysfunction. Exogenous supplementation of PK2 significantly restored brain cell function and improved cognitive performance in these mice, suggesting that PK2 may play an important role in maintaining cerebral function after surgery.\n\nHowever, it remains unclear whether changes in PK2 levels in clinical patients correlate with the occurrence and severity of postoperative cognitive dysfunction. This study aims to investigate changes in circulating PK2 levels and explore their association with postoperative cognitive alterations, so as to provide evidence for the improved prevention and identification of PND.\n\nWe plan to enroll elderly patients undergoing hip replacement surgery at Nanjing First Hospital. By analyzing PK2 expression levels and dynamic changes, combined with postoperative neuropsychological scale assessments, we will evaluate the correlation between serum PK2 levels and the clinical incidence of PND, and further verify the intrinsic link between PK2 levels and the pathogenesis of PND.",[26],"Perioperative Neurocognitive Disorders",[28,29,30],"PND","PK2","Hip replacement surgery","NOT_YET_RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":22},"2026-06-01",{"date":39,"type":22},"2027-03-31",{"name":41,"class":42},"Nanjing First Hospital, Nanjing Medical University","OTHER",{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100619850","pci-with-gdmt-versus-gdmt-alone-for-patients-with-ischemic-cardiomyopathy-and-reduced-lvef-100619850","NCT07349979","PCI With GDMT Versus GDMT Alone for Patients With Ischemic Cardiomyopathy and Reduced LVEF","Percutaneous Coronary Intervention With Guideline-Directed Medical Therapy Versus Guideline-Directed Medical Therapy Alone for Patients With Ischemic Cardiomyopathy and Reduced Left Ventricular Ejection Fraction: A Randomized, Controlled, Open-Label, Multicenter PCI-GULF Trial","PCI-GULF","Inclusion Criteria:\n\n1. Age ≥18 years at screening.\n2. Documented LVEF ≤40% assessed by quantitative transthoracic echocardiography confirmed at the core laboratory within 90 days prior to randomization.\n3. Symptomatic heart failure (NYHA Functional Class II, III, or ambulatory Class IVa) or hospitalization for heart failure within the prior 12 months or NT-proBNP ≥600 pg\u002FmL.\n4. Angiographically proven CAD with at least one lesion with 1) a visually estimated diameter stenosis (DS) of ≥90% or 2) chronic total occlusion with a high likelihood (\\>80%) of PCI success, or 3) a visually estimated DS of \\\u003C90%, or 4) a ≥50% left main stenosis, with conditions 3) and 4) both requiring a QFR ≤0.80, and all planned PCI lesions considered amenable to PCI with DES by an interventional cardiologist.\n5. On stable GDMT for at least 4 weeks prior to randomization under the advisor's assessment at each site.\n6. The subject, or their legal guardian, has a clear understanding of the trial's design and procedures, provide written informed consent, and is able to comply with all follow-up procedures.\n\nExclusion Criteria:\n\n1. Class III or IV angina requiring revascularization.\n2. Any unplanned hospitalization within 30 days.\n3. Any PCI within 12 months.\n4. Any prior CABG.\n5. Cardiogenic shock or end-stage heart failure (NYHA class IVb - unable to ambulate)\n6. Non-cardiac life expectancy \\\u003C1 year at screening (e.g., malignancy, advanced liver disease).\n7. Coronary anatomy requiring surgical revascularization by local heart team determination.\n8. Coronary anatomy unsuitable for PCI.\n9. HF due to specific cardiomyopathies, including restrictive\u002Finfiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, or hypertrophic obstructive cardiomyopathy (HOCM).\n10. Severe stenosis or regurgitation of any heart valve.\n11. Contraindication to dual antiplatelet therapy or iodinated contrast.\n12. Pregnancy, lactation, or women of childbearing potential not using effective contraception. A negative urine pregnancy test is required within 7 days prior to randomization for women of childbearing potential.\n13. Participation in another interventional trial that may interfere with the PCI and GDMT as specified in this protocol.\n14. Any other circumstances that the investigator deems inappropriate for participation, including but not limited to conditions that may jeopardize patient safety, confound data interpretation, or patients unlikely to comply with study procedures.","18 Years",{"count":53,"type":22},1154,"INTERVENTIONAL",[56],"NA","To evaluate whether percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) combined with guideline-directed medical therapy (GDMT), compared to GDMT alone, reduces the time to first occurrence of major adverse cardiovascular events (MACE) during a median follow-up of at least 24 months, measured at the time the last enrolled patient reaches 12 months, in patients with ischemic cardiomyopathy and left-ventricular ejection fraction (LVEF) ≤40%. MACE is a composite of cardiovascular \\[CV\\] death, myocardial infarction (MI), heart failure (HF) related rehospitalization, heart transplantation, requirement for durable left ventricular assist device \\[LVAD\\] implantation, or worsening heart failure treated as an out-patient requiring treatment with intravenous medications.",[59,60,61],"Heart Failure With Reduced Ejection Fraction","Coronary Artery Disease","Stable GDMT",[63,64,65,66],"HFrEF","PCI","GDMT","MACE","2026-05-24",{"date":69,"type":35},"2026-05-28",{"date":71,"type":22},"2026-12-30",{"date":73,"type":22},"2028-01-30",{"name":41,"class":42},1,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":54,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":98,"leadSponsor":100,"locationsCount":75},"100618407","pulmonary-artery-denervation-for-heart-failure-with-preserved-left-ventricular-ejection-fraction-100618407","NCT07331220","Pulmonary Artery Denervation for Heart Failure With Preserved Left Ventricular Ejection Fraction","PADN-HFpEF","Inclusion Criteria:\n\n1\\. The subject, or their legal guardian, must have a clear understanding of the trial's design and treatment procedures. They must provide written informed consent before any trial-specific tests or procedures are conducted.\n\n2\\. Both male and female subjects age between 18 \\~ 85 years old. 3. Dyspnea on exertion (NYHA functional class II-IV) not explained by non-cardiac or ischemic etiology.\n\n4\\. LVEF \\>40% on imaging within 24 months prior to enrollment, with no clinical changes suggesting worsening systolic function.\n\n5\\. Elevated NT-proBNP or BNP levels meeting the following thresholds stratified by age and atrial fibrillation (AF) status:\n\n1. Patients WITHOUT atrial fibrillation:\n\n   1. Age \\\u003C50 years: BNP \\>100 pg\u002FmL or NT-proBNP \\>450 pg\u002FmL\n   2. Age 50-75 years: BNP \\>150 pg\u002FmL or NT-proBNP \\>900 pg\u002FmL\n   3. Age \\>75 years: BNP \\>200 pg\u002FmL or NT-proBNP \\>1800 pg\u002FmL\n2. Patients WITH atrial fibrillation:\n\n   1. BNP \\>150 pg\u002FmL or NT-proBNP \\>300 pg\u002FmL\n\n      6\\. Stable HF GDMT (no change in either types or dose) for ≥14 days prior to enrollment, including SGLT2i and spironolactone. Other medication, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), angiotensin receptor-neprilysin inhibitor (ARNI, sacubitril\u002Fvalsartan), beta-blockers, or calcium channel blockers (CCBs), were left at physician's discretion.\n\n      7\\. Dose changes of ACEIs, ARBs, sacubitril\u002Fvalsartan, beta-blockers, or CCBs did not exceed 100% of baseline dose (i.e., no doubling or halving).\n\n      8\\. Continuous diuretic use for ≥14 days prior to screening, with stable dose in the last 7 days.\n\n      9\\. Meet at least one of the following:\n\n   \u003C!-- -->\n\n   1. Hospitalization for decompensated HF within the past 12 months\n   2. Received intravenous loop diuretic or ultrafiltration for HF within the past 12 months\n   3. Documented resting pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) \\>15 mmHg, or exercise PCWP ≥25 mmHg, or exercise LVEDP ≥20 mmHg on right heart catheterization within the past 12 months\n   4. Echocardiographic evidence within the past 24 months of left atrial enlargement (LA anterior-posterior diameter male \\>40 mm, female \\>38 mm; LA area ≥20 cm², LA volume index ≥29 ml\u002Fm²) or left ventricular hypertrophy (interventricular septal thickness or LV posterior wall thickness ≥12 mm).\n\nExclusion Criteria:\n\n1. Hospitalization for HF within 7 days prior to screening.\n2. Participation in an interventional trial (using investigational drug or device) of a non-observational registry study within 14 days prior to screening.\n3. History of blood or bone marrow donation within 4 weeks prior to screening, or planned donation during the study.\n4. Implantation of pulmonary artery pressure monitor or pacemaker within 4 weeks prior to screening, or planned implantation during the study.\n5. Hospitalization within 30 days prior to screening for: acute ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), unstable angina, percutaneous coronary intervention (PCI), or cardiac surgery.\n6. Cardiac resynchronization therapy (CRT) within 90 days prior to screening.\n7. Planned revascularization (PCI or CABG), major cardiac surgery (including coronary artery bypass grafting, valve replacement, ventricular assist device implantation, heart transplantation, other surgery requiring thoracotomy), transcatheter aortic valve replacement (TAVR), or CRT implantation within 90 days after screening.\n8. History of femoral or jugular vein surgery.\n9. Life expectancy \\\u003C1 year at screening.\n10. Estimated glomerular filtration rate (eGFR) \\\u003C20 ml\u002Fmin\u002F1.73 m² at screening (calculated using the modified MDRD formula).\n11. BNP \\\u003C150 pg\u002Fml and NT-proBNP \\\u003C300 pg\u002Fml at screening.\n12. Serum potassium \\>5.5 mmol\u002FL at screening.\n13. Physical examination showing volume depletion at screening or randomization.\n14. Mean supine systolic blood pressure \\\u003C100 mmHg at screening or randomization.\n15. Uncontrolled hypertension, defined as mean supine systolic blood pressure ≥160 mmHg (average of three measurements) at screening.\n16. Documented stable-state LVEF \\\u003C40% within the past 24 months.\n17. Current active malignancy (excluding non-melanoma skin cancer).\n18. HF due to specific cardiomyopathies, including: restrictive\u002Finfiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, severe valvular stenosis, hypertrophic obstructive cardiomyopathy (HOCM).\n19. Chronic obstructive pulmonary disease (COPD) judged as the primary cause of dyspnea.\n20. Myocardial ischemia judged as the primary cause of dyspnea.\n21. Isolated right heart failure due to pulmonary disease.\n22. Complex congenital heart disease.\n23. History of allergic reaction to guideline-directed HF medications.\n24. Pregnant\u002Flactating women. Women of childbearing potential (WOCBP) defined as post-menarche and not permanently sterilized (hysterectomy\u002Fbilateral tubal ligation) or postmenopausal (natural amenorrhea ≥12 months without other medical cause). Sexually active WOCBP must agree to use medically accepted contraception during the study, including: \\|surgical sterilization, progestin contraceptives (oral\u002Fimplant), barrier methods (condom\u002Fdiaphragm) with spermicide, intrauterine device (IUD). Urine pregnancy test required at each visit; negative result required for continued participation.\n25. Other exclusion criteria as judged by the investigator, including but not limited to conditions that may jeopardize patient safety during study participation, factors interfering with study data interpretation, or patients unlikely to comply with study procedures\u002Frequirements.","85 Years",{"count":85,"type":22},310,[56],"To assess the impact of PADN combined with guideline-directed medical therapy (GDMT) versus a sham procedure with GDMT on clinical outcomes in heart failure (HF) patients with preserved left ventricular ejection fraction (LVEF\\>40%). Outcomes include cardiovascular death, HF-related rehospitalization, requirement for heart transplantation or need of valvular treatment or LVAD or pacemaker implantation, and worsening in outpatients (defined as requirement for intravenous therapy or diuretic intensification, including increasing the types or dose of diuretics).",[89],"Heart Failure With Preserved Ejection Fraction",[91,92,93,94],"Pulmonary artery denervation","Heart failure with preserved ejection fraction","Guideline-directed medical therapy","Clinical worsening",{"date":96,"type":35},"2026-05-27",{"date":71,"type":22},{"date":99,"type":22},"2028-12-30",{"name":41,"class":42},{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":75},"100637111","strategy-pe-real-world-treatment-strategies-for-intermediate-high-risk-pulmonary-embolism-100637111","NCT07603700","STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism","Real-World Comparative Effectiveness and Safety of Anticoagulation, Thrombolysis, and Mechanical Thrombectomy in Intermediate-Risk Acute Pulmonary Embolism: A Multicenter Prospective Cohort Study","STRATEGY-PE","Inclusion Criteria:\n\n* Age unlimited (reflecting real-world population).\n* Symptom duration of acute PE ≤ 14 days.\n* Confirmed acute PE by CTPA involving main or lobar pulmonary arteries.\n* Defined as Intermediate-High Risk PE meeting all of the following:\n* RV\u002FLV ratio ≥ 0.9 (by CT or Echocardiography).\n* Elevated cardiac biomarkers (Troponin \\> 99th percentile or BNP \\> 100 pg\u002FmL).\n* Hemodynamically stable (SBP ≥ 90 mmHg, no vasopressors required).\n* Able to provide informed consent and complete follow-up.\n\nExclusion Criteria:\n\n* Already received thrombolysis or mechanical thrombectomy for the current episode prior to enrollment.\n* Unable to obtain baseline or follow-up CTPA imaging.\n* (Note: Unlike strict RCTs, patients with cancer, renal insufficiency, or advanced age are NOT excluded to ensure real-world representativeness).",{"count":110,"type":22},1300,"This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a real-world setting. Approximately 1,300 patients will be enrolled across multiple centers in China. Patients will be followed for 90 days to assess mortality, heart function recovery, bleeding risks, and quality of life. The results will help guide personalized treatment decisions and healthcare policy.",[113,114],"Pulmonary Embolism","Venous Thromboembolism",[116,117,118,119],"Acute Pulmonary Embolism","Intermediate-High Risk","Anticoagulation","Thrombolysis","2026-05-17",{"date":122,"type":35},"2026-05-22",{"date":37,"type":22},{"date":125,"type":22},"2029-12-31",{"name":41,"class":42},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":135,"targetDuration":4,"studyType":54,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":75},"100545358","ivi-guided-versus-angiography-guided-pci-in-patients-with-diabetes-mellitus-100545358","NCT06380868","IVI-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus","Intravascular Imaging-guided Versus Angiography-guided PCI in Patients With Diabetes Mellitus: the Muticenter, Randomized, Prospective IVI-DIABETES Trial","IVI-DIABETES","Inclusion Criteria:\n\n1. Age between 18 \\~ 80 years old,\n2. Confirmed diabetes mellitus\n3. Indications for undergoing percutaneous coronary intervention using a drug-eluting stent (Invasive or quantitative fractional flow reserve (QFR or FFR) \\\u003C0.80)\n4. Silent angina, stable angina, unstable angina, or Non-ST-elevation myocardial infarction\n\nExclusion Criteria:\n\n1. Cardiogenic shock\n2. Previous coronary artery bypass graft (CABG)\n3. Left ventricular ejection fraction \\\u003C 30%\n4. Requiring oral anticoagulation medications\n5. Any planned surgery within 12 months\n6. Severe chronic kidney disease defined as an estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.73m2\n7. Platelet count \\\u003C 100,000 mm3\n8. Contraindication to study medications or metal\n9. Women of childbearing potential\n10. Life expectancy \\\u003C 1 year\n11. Any condition likely to interfere with study processes including medication compliance or follow-up visits (e.g. dementia, alcohol abuse, severe frailty, long distance to travel for follow-up visits, etc.)",{"count":136,"type":22},1332,[56],"Intravascular ultrasound (IVUS) serves as a beneficial instrument during percutaneous coronary intervention (PCI) procedures, affording insight into lesion characteristics and stent implantation. The ULTIMATE trial recently evidenced that IVUS-guided Drug-Eluting Stent (DES) implantation notably ameliorated clinical outcomes in all-comers, especially in patients who underwent an optimal procedure defined by IVUS, as opposed to angiography guidance, resonating with findings from the IVUS-XPL study, OCTOBER trial, and RENOVATE COMPLEX PCI trial, further confirmed by more recent IVUS-ACS trial.\n\nOptical coherence tomography (OCT) has a resolution 10 times higher than that of IVUS and can provide valuable information at each step of PCI.\n\nRegrettably, a dearth of prospective, randomized, multicenter trials exists that scrutinize the benefits of IVI-guided as opposed to angiography-guided PCI in patients suffering from diabetes mellitus. However, several trials have presented subgroup analyses reporting the reduction of clinical events by IVUS but not OCT guidance in patients with diabetes mellitus, which served as the foundation for the design of this trial.",[140],"Diabetes","RECRUITING","2026-05-15",{"date":144,"type":35},"2026-05-19",{"date":146,"type":35},"2024-07-17",{"date":148,"type":22},"2027-07-20",{"name":41,"class":42},{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":158,"targetDuration":160,"studyType":23,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},"100634254","coronary-and-myocardial-evaluation-by-cardiac-ct-for-acute-myocardial-infarction-100634254","NCT07537296","Coronary and Myocardial Evaluation by Cardiac CT for Acute Myocardial Infarction","Multimodal Cardiac CT-Derived High-Risk Coronary and Myocardial Features for Predicting Adverse Outcomes After PCI in Patients With Acute Myocardial Infarction: A Multicenter Prospective Cohort Study","COMET-AMI","Inclusion Criteria:\n\n* Age ≥18 years\n* AMI within the previous 4 weeks, including STEMI or NSTEMI\n* PCI performed for ACS culprit lesion according to current guidelines\n* Hemodynamically stable\n* Willingness to undergo multimodal cardiac CT within 7 days after PCI\n* Willingness to participate in telephone follow-up\n\nExclusion Criteria:\n\n* Contraindications to cardiac CT (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² or iodine contrast allergy)\n* Previous coronary artery bypass graft surgery (CABG)\n* History of heart failure or previous myocardial infarction\n* Severe arrhythmia or structural heart disease\n* Poor image quality or missing CT data\n* Expected survival \\\u003C6 months",{"count":159,"type":22},1000,"5 Years","Acute myocardial infarction (AMI) remains a major cause of mortality and morbidity worldwide. Although percutaneous coronary intervention (PCI) combined with guideline-directed medical therapy has substantially improved survival, many patients continue to experience adverse cardiovascular events after revascularization, including recurrent ischemic events, heart failure, and malignant arrhythmias. Therefore, accurate risk stratification after PCI is essential for optimizing clinical management and improving long-term outcomes. However, currently available risk prediction tools are limited by suboptimal predictive performance or restricted clinical accessibility.\n\nCardiac imaging plays a central role in post-AMI evaluation. Echocardiography is routinely recommended after PCI to assess cardiac structure and function and to exclude early mechanical complications. Nevertheless, its ability to predict subsequent ventricular remodeling and long-term clinical outcomes is limited. Cardiac magnetic resonance imaging (CMR) is considered the reference standard for myocardial tissue characterization and provides important prognostic markers such as infarct size, microvascular obstruction, and intramyocardial hemorrhage. However, the routine use of CMR in patients with AMI is constrained by limited availability, high cost, and relatively long examination time. In addition, CMR does not directly evaluate coronary artery anatomy or plaque characteristics, which are important determinants of recurrent ischemic events.\n\nRecent advances in cardiac computed tomography (CT) have enabled comprehensive assessment of coronary artery disease. Beyond evaluating coronary stenosis, coronary CT angiography can identify high-risk plaque features associated with plaque vulnerability. Furthermore, emerging CT-based techniques allow simultaneous assessment of coronary physiology, perivascular inflammation, myocardial structure and function, and myocardial tissue characteristics. CT-derived fractional flow reserve (CT-FFR) enables noninvasive functional assessment of coronary lesions, while the fat attenuation index (FAI) reflects pericoronary inflammatory activity. In addition, delayed iodine enhancement and dual-energy CT techniques allow evaluation of myocardial injury and fibrosis, and CT-derived extracellular volume fraction (ECV) provides quantitative assessment of myocardial fibrosis. These advances suggest that multimodal cardiac CT may provide an integrated imaging approach for comprehensive risk assessment after AMI.\n\nThe COMET-AMI study (Coronary and Myocardial Evaluation by Multimodal Cardiac CT in Acute Myocardial Infarction) is a prospective, multicenter cohort study designed to evaluate the prognostic value of multimodal cardiac CT in patients with AMI after PCI. A total of 1,000 patients with AMI undergoing successful PCI will be prospectively enrolled. All participants will undergo multimodal cardiac CT within 7 days after PCI to assess coronary plaque characteristics, coronary physiology, pericoronary adipose tissue inflammation, cardiac structure and function, and myocardial tissue features. A subset of participants will also undergo cardiac magnetic resonance imaging for validation of CT-derived myocardial tissue parameters.\n\nComprehensive clinical information, including demographic characteristics, cardiovascular risk factors, medication history, laboratory biomarkers, and procedural data, will be collected. Quantitative and qualitative analyses of coronary plaques will be performed using dedicated software to assess plaque burden, plaque composition, remodeling characteristics, and high-risk plaque features. Additional CT-derived parameters such as CT-FFR, myocardial strain, pericoronary fat attenuation index, and extracellular volume fraction will also be analyzed.\n\nParticipants will be followed longitudinally through outpatient visits, telephone interviews, and electronic medical record review for up to five years after PCI. The primary outcomes include composite thrombotic events (cardiac death, recurrent myocardial infarction, and urgent or clinically driven revascularization). Secondary outcomes include heart failure and major arrhythmic events such as new-onset heart failure, sustained ventricular arrhythmia, implantable cardioverter-defibrillator implantation, sudden cardiac death, or resuscitated cardiac arrest. All clinical events will be independently adjudicated by a blinded clinical events committee.\n\nUsing multimodal cardiac CT-derived imaging biomarkers in combination with clinical and laboratory data, machine learning-based predictive models will be developed to identify key determinants of adverse outcomes after PCI in patients with AMI. The results of this study may provide a novel imaging-based risk stratification strategy and facilitate personalized management for patients with AMI after PCI.",[163],"Acute Myocardial Infarction (AMI)","2026-04-12",{"date":166,"type":35},"2026-04-17",{"date":168,"type":35},"2026-01-01",{"date":170,"type":22},"2030-12-31",{"name":41,"class":42},2,{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":83,"enrollmentInfo":181,"targetDuration":4,"studyType":54,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":172},"100469791","improving-blood-lipid-management-in-symptomatic-intracranial-atherosclerotic-stenosis-on-clinical-outcome-100469791","NCT05397405","Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome","A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）","sICASBLM","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment\n3. low density lipoprotein cholesterol \\> 70mg\u002Fdl (1.8mmol\u002FL)\n4. Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained.\n5. Lipid-lowering indications of statins\n6. Signed an approved informed consents\n\nExclusion Criteria:\n\n1. Contraindications to statins\n2. There are contraindications to MRI examination or cannot accept MRI examination\n3. Stenosis caused by vasculitis, arterial dissection and moyamoya disease\n4. Patients with active bleeding or obvious bleeding tendency\n5. Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating\n6. Uncontrolled severe diabetes and hypertension\n7. Other conditions inappropriate for inclusion judged by investigators",{"count":182,"type":22},180,[56],"sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\\>1.8mmol\u002FL) without endovascular therapy.",[186],"Intracranial Artery Stenosis",[188,189,190,191],"symptomatic intracranial atherosclerotic stenosis","stroke","blood lipid management","PCSK9 inhibitors","2026-04-10",{"date":194,"type":35},"2026-04-15",{"date":196,"type":35},"2022-05-23",{"date":198,"type":22},"2026-05-01",{"name":41,"class":42},{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":208,"targetDuration":210,"studyType":23,"phases":4,"briefSummary":211,"conditions":212,"keywords":215,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":75},"100375990","circulating-non-coding-rna-in-acute-ischemic-stroke-aisrna-100375990","NCT04175691","Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)","AISRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 72 hours of symptom onset\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n-a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases",{"count":209,"type":22},500,"90 Days","AISRNA is to analyze the expression pattern of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA) by next-generation sequencing in patients with acute ischemic stroke and healthy control. The candidate circRNA\u002FmiRNA\u002FlncRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.",[213,214],"Acute Stroke","Ischemic Stroke",[216,217,218,219],"acute ischemic stroke","noncoding RNA","clinical significance","outcome",{"date":194,"type":35},{"date":222,"type":35},"2019-11-24",{"date":224,"type":22},"2026-12-31",{"name":41,"class":42},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":18,"enrollmentInfo":233,"targetDuration":4,"studyType":54,"phases":235,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":75},"100616544","phase-4-eradication-of-helicobacter-pylori-improves-metabolic-syndrome-through-modulation-of-gut-microbiota-100616544","NCT07306988","Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.","Mechanisms of Gut Microbiota in Improving Metabolic Syndrome-Related Parameters Following Helicobacter Pylori Eradication","Inclusion Criteria:\n\n* For H. pylori-naïve infected patients with newly diagnosed metabolic syndrome (MS):\n\n  1. Aged 18-65 years;\n  2. Confirmed H. pylori-positive status by urea breath test (UBT), with no prior eradication therapy;\n  3. Newly diagnosed MS according to the Chinese Diabetes Society (CDS, 2004 Chinese criteria) ;\n  4. Voluntarily join the trial and sign informed consent.\n* For H. pylori-negative healthy controls with normal metabolism:\n\n  1. Aged 18-65 years;\n  2. Confirmed H. pylori-negative status by UBT;\n  3. Normal metabolic parameters (e.g., blood glucose, lipid profile, blood pressure) without MS;\n  4. Voluntarily join the trial and sign informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to study drugs (e.g., penicillin, amoxicillin, vonoprazan);\n2. Active peptic ulcer confirmed by endoscopy;\n3. Prior history of H. pylori eradication therapy;\n4. Use of medications for metabolic regulation (e.g., hypoglycemic agents, lipid-lowering drugs, weight-loss drugs)\n5. Recent use of antibiotics or bismuth (within 4 weeks) or H2-receptor antagonists\u002FPPIs (within 2 weeks) before enrollment;\n6. Current use of corticosteroids, NSAIDs, or anticoagulants;\n7. History of esophageal or gastric surgery;\n8. Pregnant or breastfeeding women;\n9. Severe comorbidities (e.g., hepatic, cardiovascular, pulmonary, renal diseases, inflammatory bowel disease);\n10. Chronic alcohol abuse (\\>40 g\u002Fday for men, \\>20 g\u002Fday for women);\n11. Malignancies (e.g., gastric mucosa-associated lymphoid tissue \\[MALT\\] lymphoma).",{"count":234,"type":22},120,[236],"PHASE4","The Role of Gut Microbiota in the Mechanism of Helicobacter pylori Eradication-Induced Amelioration of Metabolic Syndrome-Related Parameters\n\nStudy Sponsor: Nanjing First Hospital Principal Investigator: Dr. Wanli Liu Department: Gastroenterology Study Duration: February 2025 - August 2025\n\nKey Information for Patients and Families\n\n1. What is this study about? This study aims to understand how treating a common stomach infection caused by Helicobacter pylori (Hp) might improve metabolic health issues like high blood sugar, cholesterol problems, or obesity (collectively called metabolic syndrome). Specifically, it explores whether adding probiotics (good bacteria) or a natural compound called berberine (BBR) to standard Hp treatment can enhance these benefits by improving gut bacteria balance.\n2. Who can participate? Patients: Adults aged 18-65 with both Helicobacter pylori infection (confirmed by a breath test) and newly diagnosed metabolic syndrome (based on waist size, blood sugar, cholesterol, or blood pressure).\n\n   Healthy Volunteers: Adults aged 18-65 with no Hp infection and normal metabolic health (to compare results).\n\n   Exclusions:\n\n   Allergy to study medications (e.g., penicillin).\n\n   Previous Hp treatment, recent antibiotic\u002Fsteroid use, pregnancy, or serious medical conditions (e.g., liver\u002Fkidney disease).\n3. What will participants do?\n\n   Treatment Groups:\n\n   Group A: Take two medications (vonoprazan + amoxicillin) for 14 days.\n\n   Group B: Take the two medications + probiotics (Bifidobacterium tablets).\n\n   Group C: Take the two medications + berberine (a plant-based supplement).\n\n   Tests:\n\n   Before treatment: Breath test, blood tests (blood sugar, cholesterol, inflammation markers), stool sample analysis (gut bacteria), and body measurements (weight, waist size).\n\n   After treatment (1 month): Repeat tests to check Hp eradication and metabolic improvements.\n4. Possible Benefits and Risks\n\n   Benefits:\n\n   Free Hp treatment and metabolic health monitoring.\n\n   Potential improvement in blood sugar, cholesterol, or weight.\n\n   Contribution to future treatments for metabolic syndrome.\n\n   Risks:\n\n   Mild side effects (e.g., nausea, diarrhea, stomach pain) from medications.\n\n   Discomfort from blood draws or stool sample collection.\n5. How are participants protected? All treatments are FDA-approved or widely used in clinical practice.\n\nEthical review ensures participant safety.\n\nYou can withdraw at any time without affecting your regular care.\n\nInformation for Health Care Providers\n\n1. Study Design Type: Prospective, single-center, open-label, randomized controlled trial.\n\n   Population: 140 participants (120 Hp+ patients with metabolic syndrome; 20 Hp- healthy controls).\n\n   Intervention:\n\n   Group A: Vonoprazan (20 mg bid) + amoxicillin (1 g tid) for 14 days.\n\n   Group B: Group A + Bifidobacterium tetragenous probiotic (3 tablets tid).\n\n   Group C: Group A + berberine (3 tablets tid).\n\n   Primary Outcomes:\n\n   Hp eradication rate (confirmed by urea breath test).\n\n   Changes in metabolic parameters (fasting glucose, HbA1c, lipid profile).\n\n   Gut microbiota composition (16S rRNA sequencing).\n\n   Secondary Outcomes:\n\n   Multi-omics analysis (inflammation markers, endotoxins, short-chain fatty acids, bile acids).\n2. Scientific Rationale Hp and Metabolic Syndrome: Epidemiological evidence links Hp infection to metabolic dysfunction, possibly via chronic inflammation. Eradication may partially reverse insulin resistance and dyslipidemia.\n\n   Gut Microbiota as Mediator: Hp eradication alters gut microbiota, which regulates metabolic homeostasis through metabolites (e.g., SCFAs), bile acid metabolism, and inflammatory pathways. Probiotics\u002FBBR may enhance these effects.\n3. Methodology Randomization: Block randomization (block size = 4) using SAS 9.4.\n\n   Assessments:\n\n   Metabolic Parameters: Fasting glucose, HbA1c, lipid profile, BMI.\n\n   Microbiome: 16S rRNA sequencing (α\u002Fβ diversity, taxa abundance).\n\n   Multi-omics: ELISA (TNF-α, IL-6), GC-MS (SCFAs), UPLC-MS (bile acids).\n\n   Statistical Analysis:\n\n   Microbiome: QIIME2, LEfSe, PICRUSt2.\n\n   Multi-omics: limma, SparCC, sPLS-DA.\n\n   Clinical data: ANOVA, χ² tests (SPSS v25.0).\n4. Clinical Implications Clarify whether probiotics or BBR add value to Hp eradication in improving metabolic health.\n\nIdentify gut microbiota-driven mechanisms linking Hp eradication to metabolic benefits.\n\nResources for Participants\n\nStudy Flowchart:\n\nScreening: Breath test, blood\u002Fstool tests (1 week).\n\nTreatment: 14 days of medication.\n\nFollow-up: Repeat tests at 1 month.\n\nContact Information:\n\nDr. Wanli Liu: +86-18951670222\n\nNanjing First Hospital Gastroenterology Department.\n\nFAQ Sheet:\n\nCan I take my regular medications? Yes, unless they interfere with Hp treatment (e.g., PPIs).\n\nWhat if I miss a dose? Contact the study team immediately.\n\nEthical Compliance Approved by the Institutional Review Board of Nanjing First Hospital.\n\nComplies with the Declaration of Helsinki and China's ethical guidelines.\n\nInformed consent required for participation.",[239,240],"HELICOBACTER PYLORI INFECTIONS","Metabolic Syndrome","2026-04-08",{"date":243,"type":35},"2026-04-13",{"date":245,"type":35},"2025-04-17",{"date":247,"type":22},"2026-06-30",{"name":41,"class":42},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":17,"minAge":257,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":54,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":75},"100428829","transcatheter-self-expandable-valve-implantation-for-the-treatment-of-severe-native-aortic-regurgitation-100428829","NCT04864145","Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation","Transcatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation: a Prospective, Multicenter, Randomized Study","SEASON-AR","Inclusion Criteria:\n\n1. Procedural indications: symptomatic severe aortic regurgitation; no symptom plus left ventricular ejection fraction ≤ 55% or left ventricular end-diastolic dimension (LVEDD) \\> 65mm or left ventricular end-systolic dimension (LVESD) \\> 50mm;\n2. Severe aortic valve regurgitation, and mean pressure gradient \\\u003C 20mmHg; Annular perimeter ≤ 85 mm;\n3. The ratio of the perimeter of the left ventricular outflow tract 4mm to the perimeter of the valve annulus is 0.95-1.05;\n4. STS score ≥8 or moderate to severe frailty or refused surgical valve replacement or presence of any of the following factors judged to be difficult to perform the surgical valve replacement:\n\n   1. Severe aorta calcification or active ascending aorta atherosclerotic plaque\n   2. History of mediastinum radiotherapy\n   3. Past mediastinitis\n   4. Presence of unobstructed coronary bypass implants\n   5. Previous more than two cardiothoracic surgeries\n   6. Liver cirrhosis\n   7. Other surgical risk factors\n\nExclusion Criteria:\n\n1. Age \\\u003C 60 years old;\n2. Ascending aorta diameter \\>45mm;\n3. Coronary multi-vessel disease (SYNTAX score \\>32);\n4. Life expectancy \\\u003C1 year;\n5. Left ventricular ejection fraction \\\u003C30%;\n6. Acute myocardial infarction within 30 days;\n7. Allergies or contraindications to related drugs (aspirin, clopidogrel, warfarin, or contrast agents);\n8. Other situations judged by the researcher as unsuitable for participating in the study.","60 Years","90 Years",{"count":260,"type":22},210,[56],"Prospective, multicenter, randomized trial.",[264],"Aortic Valve Disease","2026-04-07",{"date":241,"type":35},{"date":268,"type":35},"2021-05-21",{"date":270,"type":22},"2031-05-30",{"name":41,"class":42},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":75},"100470791","different-treatment-strategies-on-prognosis-of-acute-ischemic-strokeaisdts-100470791","NCT05410457","Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS)","Study on the Effect of Different Treatment Strategies on Prognosis of Acute Ischemic Stroke(AISDTS)","Inclusion Criteria:\n\n* A) ≥18 years of age; B) hospital admission for ischemic stroke; C) Signed informed consent.\n\nExclusion Criteria:\n\n* A) patients with incomplete clinical information; B) hospitalization observation time less than 24 hours; C) recent trauma, severe inflammation, severe liver and kidney dysfunction, progressive malignance and other serious diseases; D) baseline mRS score\\>2; E) informed consent is not signed.",{"count":280,"type":22},5000,"AISDTS is a prospective registry study, in which clinical information, examination and imaging data of patients with acute ischemic stroke receiving different treatment strategies were collected, grouped and statistically analyzed, and corresponding clinical prediction models were constructed to explore the role of clinical biological indicators in the occurrence and development of stroke.",[214],[284,285,286,287,288,289,290,291],"ischemic stroke","clincial indicators","thrombolysis","thrombectomy","neuroimaging","genetics","one-stop multimodal-MRI","stroke related complications","2026-04-06",{"date":294,"type":35},"2026-04-09",{"date":296,"type":35},"2022-05-24",{"date":298,"type":22},"2027-06-24",{"name":41,"class":42},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":258,"enrollmentInfo":308,"targetDuration":210,"studyType":23,"phases":4,"briefSummary":310,"conditions":311,"keywords":315,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":317,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":75},"100380222","circulating-non-coding-rna-in-acute-ischemic-stroke-with-endovascular-treatment-evtrna-100380222","NCT04230785","Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","EVTRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 24 hours of symptom onset and treat with endovascular therapy\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n* a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases",{"count":309,"type":22},300,"EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and\u002For after endovascular treatment. The candidate circRNA\u002FlncRNA\u002FmiRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.",[312,313,314],"Stroke, Acute","Stroke, Ischemic","Endovascular Treatment",[216,217,316,218,219],"endovascular treatment",{"date":294,"type":35},{"date":319,"type":35},"2020-03-15",{"date":321,"type":22},"2026-12-01",{"name":41,"class":42},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":330,"targetDuration":4,"studyType":54,"phases":332,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":341,"leadSponsor":343,"locationsCount":4},"100631774","phase-3-jianpi-lishi-jiedu-granules-for-prevention-of-postoperative-recurrence-in-colorectal-advanced-adenomas-100631774","NCT07505056","Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas","A Multicenter, Randomized, Double-blind, Parallel-controlled Clinical Study on the Intervention of Jianpi Lishi Jiedu Granules for Postoperative Recurrence of Colorectal Advanced Adenomas","Inclusion Criteria:\n\n1. Aged between 18 and 80 years, male or female\n2. Have undergone endoscopic resection of colorectal adenoma within the past 2 weeks (cold snare resection or endoscopic mucosal resection for adenomas \\\u003C 20 mm, or endoscopic submucosal dissection for adenomas ≥ 20 mm), and have been diagnosed with colorectal advanced adenoma by endoscopy and pathology\n3. Traditional Chinese Medicine (TCM) syndrome type conforms to the Spleen Deficiency and Dampness Toxin syndrome\n4. The patient is fully informed, voluntarily consents to data collection, and has signed the informed consent form\n\nExclusion Criteria:\n\n1. Patients with diseases such as familial polyposis, inflammatory bowel disease, serrated polyposis syndrome, Peutz-Jeghers syndrome, or other hereditary polyposis syndromes\n2. Patients with long-term use of medications such as aspirin, metformin, intestinal flora regulators, folic acid, calcium preparations, and vitamin D\n3. Patients with a bleeding tendency (referring to a pathological state where hemostasis is difficult after spontaneous bleeding or minor trauma due to coagulation dysfunction or vascular structural issues) or those currently using anticoagulant medications (e.g., aspirin, clopidogrel)\n4. Patients in the active phase of inflammatory bowel disease (such as ulcerative colitis, Crohn's disease, etc.), with a history of intestinal bleeding, or a history of intestinal surgery\n5. Patients with high-grade intraepithelial neoplasia involving the vascular system, lymphatic tumor thrombi, or small arteries; patients with biopsy pathology confirming suspected malignancy or established malignancy\n6. Pregnant or lactating women, or patients planning a recent pregnancy\n7. Patients with an allergic constitution or a history of allergies to multiple drugs\n8. Patients with severe heart, brain, lung, liver, kidney diseases, or mental disorders who cannot tolerate colonoscopy, treatment, and clinical intervention\n9. Patients currently participating in other clinical trials or those previously involved in trials related to this study.",{"count":331,"type":22},376,[333],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Jianpi Lishi Jiedu Granules in preventing postoperative recurrence of colorectal advanced adenoma. A total of 376 patients aged 18-80 years with endoscopically resected advanced adenoma and diagnosed with Spleen Deficiency and Dampness Toxin syndrome will be enrolled and randomly assigned to receive either Jianpi Lishi Jiedu Granules or placebo for 3 months. The primary endpoint is the adenoma recurrence rate at 1 year post-treatment, assessed by colonoscopy and pathological examination. Secondary endpoints include malignant transformation rate, TCM syndrome improvement, quality of life, gastrointestinal symptoms, and exploratory analyses of gut microbiota and inflammatory cytokines.",[336],"Colorectal Adenoma","2026-03-26",{"date":339,"type":35},"2026-04-01",{"date":198,"type":22},{"date":342,"type":22},"2028-02-29",{"name":41,"class":42},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":352,"targetDuration":4,"studyType":54,"phases":354,"briefSummary":355,"conditions":356,"keywords":359,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":371},"100600153","super-high-pressure-balloon-versus-intravascular-lithotripsy-to-prepare-severely-calcified-coronary-lesions-100600153","NCT07093788","Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions","Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions: a Randomized Controlled Trial (Shape)","Shape","Inclusion Criteria:\n\n* Age \\> 18 years and \\\u003C 80 years\n* Presented as asymptomatic angina, stable angina, unstable angina, prior myocardial infarction (MI), or non-ST-elevation myocardial infarction (NSTEMI).\n* Have an indication for drug-eluting stent (DES) implantation\n* Denovo coronary artery calcified lesions\n* Target lesion diameter stenosis ≥ 70%, or target lesion diameter stenosis between ≥ 50% and \\\u003C 70%, accompanied by evidence of myocardial ischemia(such as fractional flow reserve (FFR) ≤ 0.80 or minimal lumen area (MLA) ≤ 4.0 mm²).\n* Reference vessel diameter of the target vessel between 2.5 mm - 4.5 mm\n* Maximum calcium arc within the lesion ≥ 270⁰ assessed by optical coherence tomography (OCT) or intravascular ultrasound (IVUS)\n* Unsatisfactory lesion preparation with non-compliant balloon, defined as baseline diameter stenosis reduction of \\\u003C 30% under maximal inflation pressure.\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Presented as acute ST-segment elevation myocardial infarction (STEMI), cardiogenic shock and multiple organ failure\n* Presented as severe contrast agent allergy\n* Intolerant to dual antiplatelet therapy (DAPT) and\u002For anticoagulation therapy\n* Presented as active phase of autoimmune disease\n* Calcified nodules or eccentric calcification lesions\n* Failure to reach the target lesion with guidewires or catheters\n* Complex coronary bifurcation lesions\n* Target vessel thrombosis or aneurysm within 10 mm of the target lesion",{"count":353,"type":22},78,[56],"this trial aimed to evaluate the stent expansion through intravascular imaging (optical coherence tomography (OCT) \\& intravascular ultrasound (IVUS)) among individuals underwent different preparation techniques ,then comparing the efficacy and safety of super high-pressure balloon to IVL in severely calcified lesions",[64,357,358],"Coronary Arterial Disease (CAD)","Calcified Coronary Lesions",[360,361,362],"super high-pressure balloon","percutaneous coronary intervention","intravascular lithotripsy","2026-03-06",{"date":365,"type":35},"2026-03-10",{"date":367,"type":35},"2025-09-01",{"date":369,"type":22},"2027-06-30",{"name":41,"class":42},3,{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":54,"phases":382,"briefSummary":383,"conditions":384,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":397,"locationsCount":75},"100622612","ultrasound-guided-non-invasive-simulation-in-anesthesia-residency-training-100622612","NCT07385885","Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training","Application of Ultrasound-guided Non-invasive Simulated Puncture Technique in Standardized Residency Training in Anesthesiology","non-invasive","Inclusion Criteria:\n\n\\~Anesthesiology residents participating in the standardized residency training program in the Department of Anesthesiology at Nanjing First Hospital between October 2024 and October 2026.\n\nExclusion Criteria:\n\n* Residents with prior experience in performing nerve block procedures.\n* Residents currently participating in other teaching or research studies related to nerve blocks.",{"count":381,"type":22},30,[56],"Study Aim: This trial evaluates if a novel non-invasive, AI-assisted simulation training improves ultrasound-guided needle visualization skills in anesthesia residents.\n\nDesign: Trainees were randomized into two groups:\n\nIntervention: AI-based, non-invasive simulated needle puncture training. Control: Conventional ultrasound teaching. Key Outcomes: The primary outcome is objective needle tip visibility. Secondary outcomes include anatomical identification, correct view acquisition, operator confidence, and overall scanning performance.\n\nAssessment: Outcomes are measured via blinded expert evaluation and theoretical tests.\n\nThe goal of this randomized controlled clinical trial is to determine whether an ultrasound-guided non-invasive simulated needle puncture training technique can improve ultrasound-guided needle visualization skills in anesthesiology residents undergoing standardized residency training. The study is conducted in anesthesiology residents enrolled in a standardized residency training program.\n\nThe main questions it aims to answer are:\n\n1. Does non-invasive simulated needle puncture training improve objective needle tip visibility during ultrasound-guided peripheral nerve block procedures?\n2. Does this training method improve anatomical structure identification, acquisition of correct block views, operator confidence, and overall scanning performance compared with conventional ultrasound teaching? Researchers will compare a non-invasive simulated needle puncture training group with a conventional ultrasound teaching group to see if the simulated training technique leads to superior needle visualization and procedural performance.\n\nParticipants will:\n\nReceive standardized theoretical instruction on ultrasound- guided peripheral nerve blocks; Be randomly assigned to either non-invasive simulated needle puncture training using an artificial intelligence-assisted system or conventional ultrasound scanning training; Perform ultrasound scanning and simulated or conventional practice on healthy volunteers; Undergo theoretical examinations and blinded expert assessments of ultrasound scanning performance and needle visualization outcomes.",[385,386,387,388,389,390],"Ultrasound","Needle","Residency","Anesthesiology","Training","Non-invasive","2026-02-03",{"date":393,"type":35},"2026-02-04",{"date":395,"type":22},"2026-02-01",{"date":99,"type":22},{"name":41,"class":42},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":83,"enrollmentInfo":405,"targetDuration":4,"studyType":54,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":75},"100623484","thyroid-cartilage-plane-vs-superior-laryngeal-nerve-space-block-in-awake-tracheal-intubation-100623484","NCT07397234","Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation","Thyroid Cartilage Plane Versus Superior Laryngeal Nerve Space for Ultrasound-guided Superior Laryngeal Nerve Block in Awake Tracheal Intubation: a Randomised Non-inferiority Clinical Trial","Inclusion Criteria:\n\n1. Patients scheduled for awake tracheal intubation under general anesthesia.\n2. Patients with difficult airways (e.g., limited cervical spine mobility, full stomach, partial airway obstruction, craniofacial deformities or trauma, micrognathia, mouth opening \\\u003C3cm, Mallampati III or IV classification) posing challenges for mask ventilation or intubation.\n3. Age between 18 and 85 years old.\n4. Gender is not restricted.\n5. ASA classification of I - III.\n\nExclusion Criteria:\n\n1. Cardiovascular dysfunction or arterial aneurysms.\n2. Mental or neurological disorders or concomitant arterial aneurysms.\n3. Infection at the puncture site.\n4. Allergy to local anesthetics.\n5. Continuous use of antiplatelet or anticoagulant medications preoperatively.\n6. Hoarseness or coughing while drinking water.\n7. Bronchial asthma.\n8. Participation in other clinical trials within the previous 3 months before enrollment 9.r current participation in other clinical trials.",{"count":406,"type":22},94,[56],"The aim of this clinical trial is to compare the effectiveness and safety of ultrasound-guided thyroid cartilage plane approach with the superior laryngeal nerve space approach for superior laryngeal nerve block in awake tracheal intubation. Patients were randomized into the thyroid cartilage plane block group (T group) or the superior laryngeal nerve space block group (C group). In Group T, bilateral thyroid cartilage plane block was performed under ultrasound with thyroid cartilage as the landmark, and local anesthetic was injected on the surface of the thyroid cartilage. In Group C, local anesthetic was injected into the space between the thyrohyoid membrane and muscle groups above.\n\nWe aim to evaluate whether the thyroid cartilage plane approach is not inferior to the superior laryngeal nerve space approach for ultrasound-guided superior laryngeal nerve block in awake tracheal intubation",[410],"Superior Laryngeal Nerve Block",[412,413,414,415,416,417],"Thyroid Cartilage plane","Superior laryngeal nerve space","Difficult airway","Superior Laryngeal Nerve","Awake tracheal intubation","Nerve block","2026-02-02",{"date":420,"type":35},"2026-02-09",{"date":422,"type":22},"2026-03-02",{"date":424,"type":22},"2027-09-01",{"name":41,"class":42},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":16,"sex":17,"minAge":257,"maxAge":19,"enrollmentInfo":433,"targetDuration":4,"studyType":54,"phases":435,"briefSummary":436,"conditions":437,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":444,"locationsCount":4},"100621733","effects-of-esketamine-and-bilateral-lower-limb-elevation-on-hemodynamic-stability-during-induction-of-general-anesthesia-in-elderly-patients-undergoing-thoracic-surgery-100621733","NCT07374458","Effects of Esketamine and Bilateral Lower Limb Elevation on Hemodynamic Stability During Induction of General Anesthesia in Elderly Patients Undergoing Thoracic Surgery","Effects of Esketamine and Bilateral Lower Limb Elevation on Hemodynamic Stability During Induction of General Anesthesia in Elderly Patients Undergoing Thoracic Surgery: A Factorial Design Study","Inclusion Criteria:\n\n* Aged 60-80 years old\n* American Society of Anesthesiologists (ASA) physical status classification Ⅰ-Ⅲ\n* Scheduled for elective thoracoscopic surgery under general anesthesia\n* Informed consent: All patients or their family members voluntarily agree to participate in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* Allergy to the drugs used in this study\n* Severe cardio-cerebro-pulmonary diseases (including myocardial infarction, heart failure, cerebral hemorrhage, stroke, respiratory failure)\n* Severe hepatic or renal diseases (Child-Pugh class C, or requiring renal replacement therapy)\n* Severe neurological diseases (including Parkinson's disease, Alzheimer's disease)\n* History of poorly controlled hypertension, or systolic blood pressure \\> 180 mmHg or mean arterial pressure (MAP) \\\u003C 70 mmHg before anesthesia induction\n* Increased intracranial pressure, glaucoma, penetrating ocular trauma, or moderate to severe pulmonary arterial hypertension\n* Spinal diseases (deformity or trauma), history of spinal surgery, abnormal skin sensation of the chest and back, infection at the puncture site, or abnormal coagulation function\n* Abdominal hypertension or lower extremity deep vein thrombosis\n* Emergency surgery\n* Body mass index (BMI) ≥ 35 kg\u002Fm²",{"count":434,"type":22},292,[56],"Video-assisted thoracoscopic surgery (VATS) is widely used in thoracic surgery due to small incisions, low stress response, and high patient tolerance. Compared with open thoracotomy, VATS has fewer complications, shorter hospital stays, and better postoperative quality of life. Despite being minimally invasive, VATS can cause severe postoperative pain via pleural\u002Flung parenchyma damage, intercostal nerve traction, and chest tube stimulation. This pain impairs patient mobility (e.g., turning over, getting out of bed), increasing risks of atelectasis and pulmonary infections. Approximately 78% of patients experience moderate-to-severe postoperative pain, and 50% receive inadequate analgesia \\[3\\]. Effective postoperative pain management is critical for recovery and reducing pulmonary infections. In recent years, combined general anesthesia with regional nerve blocks has been recommended to enhance postoperative comfort and accelerate recovery, as regional blocks alleviate pain and reduce general anesthetic dosage. Thoracic paravertebral block (TPVB), an effective regional anesthesia technique, is commonly used for postoperative analgesia in VATS.\n\nTPVB involves injecting local anesthetics near thoracic spinal nerves exiting the intervertebral foramen, blocking ipsilateral somatic and sympathetic nerves. It is mainly used for analgesia after rib fractures, breast surgery, and thoracic surgeries (open or VATS). However, preoperative TPVB blocks both thoracic nerves and sympathetic nerves. Sympathetic inhibition reduces myocardial contractility, heart rate, and peripheral vascular resistance. Additionally, rapid administration of multiple drugs during general anesthesia induction further increases hypotension risk.\n\nEsketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has stronger sedative\u002Fanalgesic effects and fewer adverse events than ketamine. Studies show sub-anesthetic doses (0.15-0.3 mg\u002Fkg) reduce induction hypotension, opioid-induced cough, and other adverse events via sympathetic stimulation, analgesia, and NMDA receptor antagonism.\n\nThe passive leg raising (PLR) test assesses fluid responsiveness in acute circulatory failure by shifting \\~300 mL of venous blood from lower limbs to the right heart. Its hemodynamic effects are reversible, avoiding fluid overload. Based on this, lower limb elevation during anesthesia induction rapidly and transiently increases venous return, reducing hypotension. Bilateral elevation enhances venous return, increases cardiac preload, improves cardiac output, and stabilizes blood pressure.\n\nGeneral anesthesia induction is a period of frequent hemodynamic fluctuations. Elderly patients, often with comorbidities and reduced physiological reserve, are more susceptible to induction-related hemodynamic disturbances (40% incidence). Sustained\u002Fsevere hypotension causes inadequate organ perfusion\u002Fischemia, increasing postoperative complications (myocardial injury, ischemic stroke, acute kidney injury). Preventing post-induction hypotension in the elderly is clinically valuable. Opioids, propofol, and muscle relaxants induce hypotension via arterial dilation and reduced peripheral resistance. TPVB-induced sympathetic block further increases hypotension risk. This study hypothesizes that esketamine administration or lower limb elevation during induction reduces hypotension incidence in elderly VATS patients with TPVB.",[438],"Post Induction Hypotension","2026-01-25",{"date":441,"type":35},"2026-01-28",{"date":395,"type":22},{"date":224,"type":22},{"name":41,"class":42},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":54,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":463,"leadSponsor":465,"locationsCount":4},"100619843","combined-mitral-and-tricuspid-versus-isolated-mitral-transcatheter-edge-to-edge-repair-for-mitral-regurgitation-with-tricuspid-regurgitation-dual-teer-trial-100619843","NCT07349888","Combined Mitral and Tricuspid Versus Isolated Mitral Transcatheter Edge-to-Edge Repair for Mitral Regurgitation With Tricuspid Regurgitation (DUAL-TEER Trial)","Combined Mitral and Tricuspid Versus Isolated Mitral Transcatheter Edge-to-Edge Repair for Mitral Regurgitation With Tricuspid Regurgitation: A Randomized Controlled Trial","Inclusion Criteria General Inclusion Criteria\n\n* Age ≥ 18 years\n* Moderate-to-severe or severe (≥3+) degenerative mitral regurgitation (DMR) or functional mitral regurgitation (FMR) combined with severe (≥3+) functional tricuspid regurgitation (FTR)\n* New York Heart Association (NYHA) functional class II, III, or IVa\n* Anatomically suitable for transcatheter edge-to-edge repair, as assessed by the Heart Team\n* Willing and able to comply with the protocol requirements and data collection procedures\n* Capable of understanding the purpose of the trial and voluntarily providing written informed consent, either personally or via a legally authorized representative DMR Inclusion Criteria\n* Symptomatic moderate-to-severe or severe degenerative mitral regurgitation (MR ≥3+)\n* High surgical risk FMR Inclusion Criteria\n* Symptomatic moderate-to-severe or severe functional mitral regurgitation (MR ≥3+)\n\nFor ventricular FMR:\n\n* Left ventricular ejection fraction (LVEF) \\\u003C 50%\n* Persistent symptoms despite optimized guideline-directed medical therapy (GDMT) and cardiac resynchronization therapy (CRT), if indicated\n* Clinically stable for at least 30 days prior to enrollment\n\nFor atrial FMR:\n\n* Unsuitable for surgery\n* Persistent symptoms despite optimized medical therapy\n* Clinically stable for at least 30 days prior to enrollment TR Inclusion Criteria\n* Severe functional tricuspid regurgitation (TR ≥3+)\n* Persistent symptoms despite guideline-directed medical therapy (GDMT)\n* Clinically stable for at least 30 days prior to enrollment\n\nExclusion Criteria:\n\n* Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure (except dilated cardiomyopathy of ischemic or non-ischemic etiology)\n* Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)\n* Refractory heart failure requiring advanced therapies (e.g., left ventricular assist device or heart transplantation)\n* Left ventricular end-systolic diameter (LVESD) \\> 70 mm\n* Left ventricular ejection fraction (LVEF) ≤ 20%\n* Pulmonary arterial hypertension as assessed by right heart catheterization (RHC)\n* Severe right ventricular dysfunction, defined as:\n\nTricuspid annular plane systolic excursion (TAPSE) \\\u003C 10 mm, or Right ventricular tissue Doppler imaging S' \\\u003C 6 cm\u002Fs, or Fractional area change (FAC) ≤ 22%\n\n-Hemodynamic instability, defined as: Systolic blood pressure \\\u003C 90 mmHg with afterload reduction, or Cardiogenic shock requiring inotropic support, intra-aortic balloon pump, or ther mechanical circulatory support\n\n* Severe uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and\u002For diastolic blood pressure ≥ 110 mmHg)\n* Myocardial infarction or unstable angina within 30 days prior to enrollment\n* Significant untreated coronary artery disease requiring revascularization, or coronary intervention performed within 30 days prior to enrollment\n* Moderate or greater aortic valve or pulmonary valve stenosis or regurgitation Mitral valve anatomy deemed unfavorable for transcatheter edge-to-edge repair by the Heart Team, including:Moderate-to-severe calcification in the grasping zone; Mitral valve orifice area \\\u003C 3.5 cm²; Posterior mitral leaflet length \\\u003C 7 mm; Mitral stenosis; Leaflet perforation; Multi-segment disease or multiple chordal rupture Tricuspid valve anatomy deemed unfavorable for transcatheter edge-to-edge repair by the Heart Team, including:Moderate-to-severe calcification in the grasping zone; Coaptation gap ≥ 10 mm; Severe leaflet perforation, cleft lesions, or other conditions preventing device implantation\n* Congenital Ebstein's anomaly\n* Prior surgical or interventional procedure involving the mitral or tricuspid valve\n* Pacemaker or implantable cardioverter-defibrillator (ICD) leads interfering with proper device positioning\n* Intracardiac thrombus, vegetation, mass, or tumor in the atria or ventricles\n* Cerebrovascular accident (stroke) within 3 months prior to enrollment\n* Chronic obstructive pulmonary disease requiring continuous home oxygen therapy or long-term outpatient oral steroid treatment\n* End-stage renal disease requiring chronic dialysis\n* Vascular access limitations, including inferior vena cava filter, severely tortuous or obstructed caval system, or difficult transseptal puncture\n* Contraindications to antithrombotic therapy, or history of intracerebral hemorrhage, gastrointestinal bleeding, or bleeding disorders within 3 months prior to enrollment\n* Uncontrolled active infection, including active bacterial endocarditis\n* Severe comorbidities that may complicate treatment evaluation (e.g., coma, malignancy, or severe psychiatric disorders)\n* Pregnancy or breastfeeding\n* Life expectancy \\\u003C 1 year\n* Participation in another clinical trial that has not yet reached its primary endpoint\n* Investigator judgment that the patient is non-compliant or unlikely to complete follow-up as required",{"count":453,"type":22},404,[56],"This study aims to investigate the efficacy and safety of combined mitral and tricuspid transcatheter edge-to-edge repair (TEER) versus isolated mitral TEER in the treatment of patients with mitral regurgitation (MR) combined with tricuspid regurgitation (TR). The expected objective is to provide a more precise treatment strategy for patients with MR combined with TR, reduce surgical risks, improve survival rates and quality of life, and offer evidence for clinical practice. The main research content involves enrolling 404 patients with severe MR combined with TR, who will be randomly assigned to either the group receiving simultaneous mitral and tricuspid TEER or the group receiving isolated mitral TEER. The primary endpoint is the composite endpoint at one year postoperatively, including death during the one-year follow-up, mitral and\u002For tricuspid surgery or intervention due to mitral and\u002For tricuspid dysfunction, rehospitalization for heart failure, and an increase of \\\u003C15 points in the KCCQ score.",[457,458],"Mitral Regurgitation","Tricuspid Regurgitation","2026-01-16",{"date":461,"type":35},"2026-01-20",{"date":395,"type":22},{"date":464,"type":22},"2031-08-31",{"name":41,"class":42},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":54,"phases":475,"briefSummary":476,"conditions":477,"keywords":479,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":485,"leadSponsor":487,"locationsCount":75},"100619842","phase-4-colchicine-treatment-for-non-flow-limiting-coronary-plaque-by-coronary-cta-a-randomized-controlled-trial-100619842","NCT07349875","Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","COLOR","Inclusion Criteria\n\n1. The subject (or legal guardian) understands the trial requirements and treatment procedure, and signs the written informed consent before undergoing any protocol-specified examinations or procedures;\n2. Aged ≥18 years;\n3. Clinically diagnosed with chronic coronary syndrome (CCS);\n4. CCTA confirms ≥50% stenosis in at least one epicardial coronary artery, and CT fractional flow reserve (CT-FFR) \\>0.80.\n\nExclusion Criteria\n\n1. Unable or unwilling to provide informed consent;\n2. Unable to complete scheduled follow-up;\n3. Underwent PCI within the past 3 months;\n4. History of coronary artery bypass grafting (CABG);\n5. Diagnosis of acute coronary syndromes (ACS);\n6. No coronary plaque or plaque stenosis \\\u003C50% (confirmed by CCTA);\n7. Lesion-specific CT-FFR ≤0.80 in at least one major epicardial coronary artery;\n8. Inflammatory bowel disease (Crohn's disease\u002Fulcerative colitis) or chronic diarrhea;\n9. History of gastric ulcer or gastric bleeding;\n10. Pregnant\u002Flactating women or women of childbearing age without effective contraception;\n11. Neuromuscular disease or non-transient creatine kinase (CK) \\>3×upper limit of normal (ULN) (confirmed by ≥2 lab tests);\n12. Clinically significant non-transient hematological abnormalities (hemoglobin \\\u003C100 g\u002FL, hematocrit \\\u003C30%\u002F \\>52%, white blood cell count \\\u003C3×10⁹\u002FL, platelet count \\\u003C100×10⁹\u002FL; confirmed by ≥2 lab tests);\n13. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² (CKD-EPI formula);\n14. Liver dysfunction (alanine aminotransferase \\>3×ULN and\u002For total bilirubin \\>2×ULN);\n15. Current\u002Fplanned immunosuppressive therapy;\n16. Long-term colchicine use for other indications;\n17. Definite\u002Fsuspected colchicine allergy;\n18. Active malignant tumor (expected survival \\\u003C1 year);\n19. Use of potent CYP3A4\u002FP-glycoprotein inhibitors (e.g., cyclosporine, antiretrovirals, antifungals, erythromycin, clarithromycin) without alternative drugs.",{"count":474,"type":22},3826,[236],"This study is a prospective, multicenter, randomized controlled clinical trial designed to evaluate whether an anti-inflammatory medication can help improve heart health in patients with stable coronary artery disease.\n\n1. Research Question \\& Hypothesis We aim to determine whether adding low-dose colchicine (0.5 mg once daily) to standard medical treatment can further reduce the risk of major cardiovascular events in patients with chronic coronary syndromes (CCS), especially those with non-flow-limiting coronary plaques detected by coronary CT angiography (CCTA).\n\n   We hypothesize that colchicine, by reducing vascular inflammation, may help prevent future heart attacks, strokes, and the need for coronary revascularization.\n2. Study Population \\& Design Design: A rigorously designed, prospective, multicenter, randomized (1:1), controlled superiority trial.\n\n   Population: Adults (\\>18 years) diagnosed with CCS, identified by CCTA as having at least one coronary artery with ≥50% narrowing but without significant impact on blood flow (CT-FFR \\> 0.80).\n\n   Intervention:\n\n   Intervention Group: Standard guideline-directed medical therapy (GDMT) + colchicine 0.5 mg once daily Control Group: GDMT alone Sample Size: Approximately 3,826 participants, accounting for a 5% dropout rate.\n3. Study Endpoints Primary Endpoint: The occurrence of major adverse cardiovascular or cerebrovascular events (MACCE), including:Cardiovascular death; Ischemic stroke; Non-fatal myocardial infarction; Any coronary revascularization. Assessed for 12 months after the last patient is enrolled.\n\nSecondary Endpoints:Occurrence of MACCE over 36 months. Incidence and time to first occurrence of each event category at 12, 24, and 36 months.\n\nSafety Endpoint: Side effects related to colchicine (e.g., gastrointestinal upset, liver or kidney abnormalities, blood disorders, muscle-related reactions).",[478],"Coronary Artery Disease (CAD)",[480,478,60,481,482],"Chronic coronary syndromes","COLCHICINE","Vulnerable Plaque",{"date":461,"type":35},{"date":168,"type":35},{"date":486,"type":22},"2030-06-30",{"name":41,"class":42},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":497,"conditions":498,"keywords":501,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":508,"leadSponsor":510,"locationsCount":75},"100615825","intravascular-imaging-guided-versus-angiography--guided-pci-in-patients-with-des-isr-100615825","NCT07297641","Intravascular Imaging-Guided Versus Angiography- Guided PCI in Patients With DES-ISR","Intravascular Imaging-Guided Versus Angiography- Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis","Inclusion Criteria:\n\n(1) Patients with DES-ISR lesions; (2) Life expectancy of at least 1 year; (3) DES-ISR lesions occurring for the first time in native coronary arteries and suitable for re-PCI based on angiographic findings.\n\nExclusion Criteria:\n\n(1) Bare-metal stent in-stent restenosis (BMS-ISR). (2) Non-DES-ISR lesions. (3) Incomplete clinical and angiographic data. (4) Poor quality of IVUS or angiographic images. (5) Recurrent DES-ISR. (6) Optical coherence tomography (OCT) guidance.",{"count":496,"type":22},1500,"This study aimed to compare the clinical and angiographic outcomes of patients with DES-ISR who underwent repeat PCI with intravascular imaging or angiographic guidance.",[64,499,500],"In-stent Restenosis","Intravascular Imaging Device",[502,503,361],"in-stent restenosis","Intravascular imaging device","2025-12-09",{"date":506,"type":35},"2025-12-22",{"date":168,"type":22},{"date":509,"type":22},"2027-08-01",{"name":41,"class":42},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":518,"maxAge":4,"enrollmentInfo":519,"targetDuration":518,"studyType":23,"phases":4,"briefSummary":520,"conditions":521,"keywords":525,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":75},"100607972","clinical-application-of-somatostatin-receptor-and-norepinephrine-transporter-targeted-imaging-for-diagnosis-and-staging-of-neuroblastoma-and-pheochromocytomaparaganglioma-100607972","NCT07195500","Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma\u002FParaganglioma","the Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for the Diagnosis and Staging of Neuroblastoma and Pheochromocytoma\u002FParaganglioma","Inclusion Criteria:\n\n* Age: ≥6 months (pediatric and adult).\n* Suspected or confirmed diagnosis of neuroblastoma (NB) or pheochromocytoma\u002Fparaganglioma (PPGL).\n* Clinical indication for SSTR and\u002For NET-targeted molecular imaging for initial staging, restaging, suspected recurrence, response assessment, or treatment planning.\n* Ability to undergo PET\u002FCT or PET\u002FMRI and\u002For SPECT\u002FCT per protocol; for the PET\u002FMRI subset, no MRI contraindications.\n* Provision of written informed consent\u002Fassent per local regulations.\n* Women of childbearing potential: negative pregnancy test within 72 hours prior to tracer administration and agreement to use effective contraception during the imaging window.\n* For the multi-tracer subset (if applicable): willingness to undergo two imaging studies within a predefined window (e.g., ≤28 days) without intervening antitumor therapy.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding; breastfeeding participants unwilling to follow tracer-specific lactation interruption guidance per institutional policy.\n* Any condition that, in the investigator's judgment, precludes safe imaging or protocol compliance (e.g., uncontrolled cardiorespiratory disease, severe claustrophobia not amenable to sedation\u002Fanxiolysis).\n* Known hypersensitivity to study radiopharmaceuticals or their excipients.\n* Use of interfering medications without feasible washout:\n\nNET imaging: drugs that affect catecholamine transport\u002Fstorage (e.g., labetalol, tricyclic antidepressants, certain sympathomimetics) per site SOPs.\n\nSSTR imaging: long-acting somatostatin analogues within \\~3-4 weeks or short-acting within \\~24-48 hours, unless clinically unavoidable.\n\n* Prior therapeutic or high-dose 131I-MIBG within a period that would confound diagnostic imaging or dosimetry (e.g., within 6 months), at the investigator's discretion.\n* Contraindications to required modality-specific procedures (e.g., MRI-incompatible implants for PET\u002FMRI; iodinated\u002Fgadolinium contrast contraindication only if contrast is mandated and no alternative pathway is acceptable).\n* Inability to lie still for the required acquisition time and sedation not feasible per institutional policy.\n* Concurrent participation in an interventional study or receipt of anticancer therapy that would confound imaging interpretation within the imaging window; for multi-tracer comparisons, any interval systemic therapy between scans.","6 Months",{"count":381,"type":22},"The goal of this clinical trial is to evaluate the diagnostic efficacy of somatostatin receptor and norepinephrine transporter targeted imaging (including 18F-MFBG, 123I-MIBG, 131I-MIBG, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, 68Ga-DOTA-TOC, and other radiolabeled somatostatin analogues) in the diagnosis and staging of neuroblastoma and pheochromocytoma\u002Fparaganglioma patients aged 1-70 years. The main questions it aims to answer are:\n\nCan molecular targeted imaging using various norepinephrine transporter tracers (18F-MFBG, 123I\u002F131I-MIBG) and somatostatin receptor tracers (68Ga-DOTA-peptides series) accurately detect primary tumors and metastatic lesions in neuroblastoma\u002Fpheochromocytoma patients? What is the comparative diagnostic performance (sensitivity, specificity, accuracy) of different molecular imaging techniques compared to histopathological diagnosis as the gold standard? Researchers will compare the imaging findings from multiple tracer types with surgical pathology results to assess diagnostic accuracy and clinical staging precision.\n\nParticipants will:\n\n* Undergo screening assessments including medical history, physical examination, and laboratory tests\n* Receive intravenous injection of selected tracers (18F-MFBG, 68Ga-DOTA-NOC\u002FTATE, or other appropriate agents) at standardized doses followed by PET-CT\u002FMRI imaging at optimal time points\n* Undergo histopathological examination within 2 months post-imaging\n* Complete safety follow-up for 6 months to monitor for any adverse reactions to the imaging agents",[522,523,524],"Neuroblastoma","Pheochromocytoma","Paraganglioma",[526,527,528,529,530,531],"neuroblastoma","PET","pheochromocytoma","paraganglioma","somatostatin receptor","norepinephrine transporter","2025-09-19",{"date":534,"type":35},"2025-09-26",{"date":536,"type":35},"2024-12-25",{"date":538,"type":22},"2028-06-30",{"name":41,"class":42},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":547,"targetDuration":4,"studyType":54,"phases":549,"briefSummary":550,"conditions":551,"keywords":554,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":172},"100604726","local-anaesthetic-spread-and-sensory-block-range-of-the-retro-superior-costotransverse-ligament-space-block-100604726","NCT07153263","Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block","Comparison of Local Anaesthetic Spread Between the Retro-superior Costotransverse Ligament Space Block and Thoracic Paravertebral Block: A Three-dimensional CT Reconstruction Imaging Study","Inclusion Criteria:\n\nPatients scheduled for CT-guided lung nodule localization under local anesthesia will be selected\n\n1. aged 18-80 years\n2. BMI 18-30 kg\u002Fm²\n3. ASA classification I-III\n\nExclusion Criteria:\n\n1. Allergy to the study drug or local anesthetic;\n2. History of opioid abuse;\n3. Pre-existing skin infection at the puncture site of ITPN or TPVB;\n4. Peripheral infectious neuropathy;\n5. Dysfunction of blood coagulation",{"count":548,"type":22},50,[56],"The aim of this clinical trial is to investigate the effects of local anesthetic diffusion range and sensory block range during retro-SCTLB(retro superior costotransverse ligament space block) and TPVB(thoracic paravertebral block) in patients undergoing CT-guided lung nodule localization. The main issue of the study is to determine the differences in the diffusion range and sensory block range of local anesthetics between the retro-SCTLB and TPVB nerve block methods.",[552,553],"Pulmonary Nodules","Nerve Block",[555,556,557,558],"nerve block","TPVB","ITPB","rSCTL","2025-09-14",{"date":561,"type":35},"2025-09-16",{"date":563,"type":35},"2025-09-12",{"date":565,"type":22},"2026-09-30",{"name":41,"class":42},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":19,"enrollmentInfo":574,"targetDuration":4,"studyType":54,"phases":576,"briefSummary":577,"conditions":578,"keywords":4,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":75},"100599085","laser-assisted-ultrasound-guided-peripheral-vein-cannulation-in-cardiac-surgery-100599085","NCT07079904","Laser-assisted Ultrasound-guided Peripheral Vein Cannulation in Cardiac Surgery","Comparison of Single Operator Laser-assisted Ultrasound-guided Peripheral Vein Cannulation With Traditional Ultrasound Guidance in Patients Receiving Cardiac Surgery","Inclusion Criteria:\n\n1. aged 18-80 years\n2. BMI 18-30 kg\u002Fm²\n3. ASA classification 1-4\n\nExclusion Criteria:\n\n1. infection or hematoma at the puncture site\n2. patients mentally unstable or unable to cooperate\n3. patient refused to participate",{"count":575,"type":22},100,[56],"The aim of this clinical trial is to investigate the advantages of single-operator laser-assisted ultrasound-guidance comparing with traditional ultrasound guidance in peripheral venous catheterization.The primary question addressed is whether single-operator laser-assisted ultrasound-guidance could improve the first-attempt success rate of peripheral venous catheterization compared with traditional ultrasound guidance.",[579],"Ultrasonography, Interventional","2025-09-10",{"date":563,"type":35},{"date":583,"type":35},"2025-07-24",{"date":585,"type":22},"2026-08-30",{"name":41,"class":42},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":18,"enrollmentInfo":594,"targetDuration":4,"studyType":54,"phases":596,"briefSummary":597,"conditions":598,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":4},"100605199","huazhi-rougan-granule-as-an-add-on-therapy-for-h-pylori-infection-with-metabolic-associated-steatohepatitis-100605199","NCT07159412","Huazhi Rougan Granule as an Add-On Therapy for H. Pylori Infection With Metabolic-associated Steatohepatitis","A Randomized, Double-Blind, Placebo-Controlled Trial of Huazhi Rougan Granule Combined With High-Dose Dual Therapy for Helicobacter Pylori Infection Complicated With Metabolic-associated Steatohepatitis (Dampness-Heat Accumulation Syndrome)","Inclusion Criteria:\n\n1. Aged 18-65 years;\n2. Meeting the diagnostic criteria for metabolic-associated steatohepatitis (MASH) and the traditional Chinese medicine syndrome differentiation criteria for dampness-heat accumulation pattern;\n3. Initial treatment for H. pylori infection (positive 13C- or 14C-urea breath test);\n4. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Individuals with fatty liver caused by chronic heart failure, malnutrition, or pregnancy; those with fatty liver syndrome in encephalopathy, abetalipoproteinemia, or localized fatty liver;\n2. Patients with severe fatty liver accompanied by ascites, edema, hyponatremia, hypokalemia, or other signs suggestive of cirrhosis; those with hepatitis or cirrhosis caused by viruses, drug toxicity, autoimmune diseases, or other factors;\n3. Individuals using hepatoprotective, enzyme-lowering, or lipid-lowering medications that may interfere with efficacy evaluation;\n4. Pregnant or lactating women;\n5. Patients with severe primary cardiovascular, renal, or other life-threatening diseases;\n6. Individuals with a history of cancer;\n7. Those positive for HCV antibody, HIV antibody, or HBsAg with detectable HBV-DNA levels;\n8. Individuals with a history of alcohol abuse (≥210 g\u002Fweek for males or ≥140 g\u002Fweek for females) or substance abuse;\n9. Those with known hypersensitivity to any component of the study drug;\n10. Participation in another clinical trial within 3 months prior to screening;\n11. Use of Chinese herbal medicines for the treatment of non-alcoholic simple fatty liver within 2 weeks prior to screening;\n12. Individuals deemed unsuitable for participation by the investigator.",{"count":595,"type":22},286,[56],"This study employed a double-blind, randomized, placebo-controlled design. Eligible treatment-naïve patients with Helicobacter pylori (Hp) infection complicated by metabolic-associated steatohepatitis (MASH) (dampness-heat accumulation syndrome) were enrolled and randomly assigned to either the experimental group or the placebo control group. Both groups received a 2-week Hp eradication regimen consisting of vonoprazan (20 mg twice daily) and amoxicillin (1000 mg three times daily). The experimental group additionally received active Huazhi Rougan Granule (taken orally three times daily, one sachet each time, with a 6-day medication followed by a 1-day drug holiday per cycle), while the placebo control group received an identical matching placebo on the same schedule. The study aims to evaluate the synergistic therapeutic efficacy of Huazhi Rougan Granule in combination with the vonoprazan-amoxicillin dual therapy.",[599,600,601,602],"Helicobacter Pylori Infection","Metabolic-associated Steatohepatitis","High-dose Dual Therapy","Huazhi Rougan Granule","2025-09-05",{"date":605,"type":35},"2025-09-08",{"date":607,"type":22},"2025-08-31",{"date":609,"type":22},"2027-08-31",{"name":41,"class":42},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":83,"enrollmentInfo":618,"targetDuration":4,"studyType":54,"phases":620,"briefSummary":621,"conditions":622,"keywords":624,"overallStatus":141,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":75},"100588537","phase-4-determination-of-the-optimal-volume-of-liposomal-bupivacaine-in-adductor-canal-block-for-knee-joint-surgery-100588537","NCT06942689","Determination of the Optimal Volume of Liposomal Bupivacaine in Adductor Canal Block for Knee Joint Surgery","Determination of the Optimal Volume of Liposomal Bupivacaine in Single-Shot Adductor Canal Block for Knee Joint Surgery-A Phase I\u002FII Trial","Inclusion Criteria:\n\n* Patients undergoing elective general anesthesia for unilateral knee joint surgery.\n* Patients who provide informed consent.\n* Aged between 18 and 65 years old, regardless of gender.\n* American Society of Anesthesiologists (ASA) physical status classification of Ⅰ to Ⅲ\n* Body mass index (BMI) ≤ 35 kg\u002Fm².\n\nExclusion Criteria:\n\n* Femoral neuropathy.\n* Coagulation dysfunction.\n* Allergy to local anesthetics.\n* Infection at the puncture site.\n* History of chronic pain or opioid use.\n* Pregnancy.\n* Diabetes mellitus and peripheral neuropathy.",{"count":619,"type":22},63,[236],"Building on Bayesian design methodologies from volume optimization studies of ropivacaine in shoulder surgery, this study pioneers the application of a seamless dose-finding strategy in knee ACB. Utilizing advanced statistical models (BOIN\u002FBOP2 design), we aim to systematically evaluate the volume-effect relationship of liposomal bupivacaine, providing precise dosing recommendations to advance personalized and optimized analgesic protocols for knee surgery.",[623],"Optimal Volume of Liposomal Bupivacaine",[625,626,627,628,629],"Liposomal Bupivacaine","Adductor Canal Block","Knee Surgery","Maximum Tolerated Volume","Quadriceps Muscle Strength",{"date":605,"type":35},{"date":632,"type":35},"2025-06-01",{"date":634,"type":22},"2027-12-31",{"name":41,"class":42},""]